GLP1R and diabetes mellitus: In addition to antiplatelet agents, acting downward this cascade, novel drugs for the treatment of DM, namely GLP-1 RA, are of interest since they have been reported to revert beta cell function both in animal models, by inhibiting pancreatic beta-cell apoptosis and stimulating the proliferation and differentiation of beta-cells [49], and in human studies [17,50].